89.5% growth masks the margin transition — inventory tailwind spent, price pass is now the test

On the result sheet, a 332.5% PAT jump looks exceptional. But the headline obscures a crucial transition: 59% of profit growth is finance cost reduction from post-IPO deleveraging, not business momentum. Core EBITDA is up a more modest 20%. This quarter was as much a balance-sheet story as an operational one, and that gap between reported and organic is where the risk lives.

Revenue growth is real: ₹1,402.4 crore at +89.5% YoY reflects CP PLUS market dominance (87% of revenue) and strong IP camera mix (79% of CP PLUS). But profit progression tells a different story. The sequential decline of -1.4% in revenue and -15.9% in PAT signals that Q1 may have been a temporary peak, not a new baseline.

The key pivot on this call was price hikes and the timeline to absorb margin pressure. Management took 10-20% price increases in Q1 and targets 25% for the full year, rolling out gradually to avoid demand destruction. This is a deliberate choice: trade some near-term margin compression for volume preservation. The risk is a timing gap. If cost inflation accelerates faster than price realization, H2 could see further margin squeeze.

Capacity is being aggressively expanded. Current capacity of 2.5 million units per month is running at 85-90% utilization. Kadapa greenfield and Greater Noida manufacturing clusters will double capacity over three years. Backward integration—housing enclosures, cables via the Corelink JV, bare PCB localization—will add margin basis points but no game-changer. These are structural, not tactical, moves.

The price action tells a clear story: stock fell -5% on day 1 post-result (Aug 12) and -14.26% by day 3. By that third-day dump, the market had delivered its verdict: 89.5% revenue growth is celebrated, but sequential softness (-1.4% QoQ), exhausted inventory margins, and cautious guidance-hold-not-raise soured the optics. The stock is now ₹3,342, down 18.37% from its all-time high of ₹4,094, and sits below both the 20-day and 50-day moving averages. That's not panic selling—it's a repricing: growth is affirmed, but the margin story is now the test.

Institutional flows are cautiously optimistic: FII holdings ticked up 0.63 percentage points to 6.35% (net buying, albeit modest). DII trimmed 1.14 percentage points to 13.61%, suggesting domestic hedge funds are taking some profits or waiting for clarity on H2 margins. Promoters remain steady at 74.71%, showing no loss of faith. Bulk deal activity from February 2026 (Dixon selling, Kotak/Nomura buying at ₹1,470) is old; there is no recent insider selling near the highs—no warning signal from the promoter.

The combination of technical weakness (below SMA20/50, RSI neutral at 47), modest institutional nibbling, and no insider selling suggests the market sees opportunity in the drawdown but demands proof. That proof is H2 margin delivery.